{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:56:33Z","timestamp":1790898993509,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this study was to identify genetic mutations in patients with localized and metastatic prostate cancer, exploring the relationship between these mutations and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We conducted next-generation sequencing on tissue samples from 106 prostate cancer patients at Seoul St. Mary\u2019s Hospital, analyzing prostate-specific antigen (PSA) levels, tumor, node, metastasis (TNM) staging, Gleason score (GS), and clinical course, including treatment modalities and biochemical recurrence (BCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 65 patients with localized and 41 with metastatic prostate cancer. Significant differences were noted in PSA levels, T stage, GS, and treatment modalities. We observed prevalent single-nucleotide variations (SNVs), copy number variations (CNVs), and structural variations including gene fusions like TMPRSS2-ERG. Key predictors of metastatic prostate cancer identified were T stage, GS, PIK3CA, LRP6, LRRK2, and APOBEC3B deletion. BRCA2, BCL6, and CHEK2 were significant predictors for BCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that specific genetic mutations, including PIK3CA, LRP6, LRRK2, and BRCA2, are linked to prostate cancer metastasis and BCR. These results highlight the potential of genetic analysis in forecasting the prognosis of prostate cancer patients and guiding therapeutic decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-025-01840-5","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T04:56:38Z","timestamp":1752468998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genetic alterations of prostate cancer: in localized and metastatic prostate cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Chang Eil","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung ah","family":"Rhew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeok Jae","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyong Woo","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mee Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Youl","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"1","key":"1840_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40779-025-00599-y","volume":"12","author":"D-C Feng","year":"2025","unstructured":"Feng D-C, et al. Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046. Military Med Res. 2025;12(1):12.","journal-title":"Military Med Res"},{"issue":"1","key":"1840_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, et al. Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up. J Urol. 2022;208(1):19\u201325.","journal-title":"J Urol"},{"issue":"6","key":"1840_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209(6):1082\u201390.","journal-title":"J Urol"},{"issue":"4","key":"1840_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.21147\/j.issn.1000-9604.2023.04.08","volume":"35","author":"D Feng","year":"2023","unstructured":"Feng D, et al. Focal ablation therapy presents promising results for selectively localized prostate cancer patients. Chin J Cancer Res. 2023;35(4):424.","journal-title":"Chin J Cancer Res"},{"issue":"12","key":"1840_CR5","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.3390\/cells9122653","volume":"9","author":"G Aurilio","year":"2020","unstructured":"Aurilio G, et al. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells. 2020;9(12):2653.","journal-title":"Cells"},{"issue":"5","key":"1840_CR6","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","volume":"63","author":"H Beltran","year":"2013","unstructured":"Beltran H, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013;63(5):920\u20136.","journal-title":"Eur Urol"},{"issue":"2","key":"1840_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/15384047.2018.1523849","volume":"20","author":"S Ikeda","year":"2019","unstructured":"Ikeda S, et al. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biol Ther. 2019;20(2):219\u201326.","journal-title":"Cancer Biol Ther"},{"issue":"18","key":"1840_CR8","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697\u2013708.","journal-title":"N Engl J Med"},{"key":"1840_CR9","unstructured":"Amin MB et al. AJCC Cancer Staging Manual. 8th ed. AJCC cancer staging manual. 2017, Switzerland: Springer Cham."},{"issue":"3","key":"1840_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000481438","volume":"100","author":"W Artibani","year":"2018","unstructured":"Artibani W, et al. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int. 2018;100(3):251\u201362.","journal-title":"Urol Int"},{"issue":"1","key":"1840_CR11","first-page":"14","volume":"11","author":"CJ Paller","year":"2013","unstructured":"Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol. 2013;11(1):14\u201323.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"15","key":"1840_CR12","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/pros.21377","volume":"71","author":"D Keizman","year":"2011","unstructured":"Keizman D, et al. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. Prostate. 2011;71(15):1608\u201315.","journal-title":"Prostate"},{"issue":"10","key":"1840_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.kjms.2016.08.007","volume":"32","author":"C Ceylan","year":"2016","unstructured":"Ceylan C, Tonyali S, Keles I. Impact of positive surgical margin on biochemical recurrence following radical prostatectomy in locally advanced prostate cancer. Kaohsiung J Med Sci. 2016;32(10):514\u20137.","journal-title":"Kaohsiung J Med Sci"},{"issue":"10","key":"1840_CR14","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s10147-021-01977-x","volume":"26","author":"S Morizane","year":"2021","unstructured":"Morizane S, et al. Impact of positive surgical margin status in predicting early biochemical recurrence after robot-assisted radical prostatectomy. Int J Clin Oncol. 2021;26(10):1961\u20137.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"1840_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12957-018-1433-3","volume":"16","author":"L Zhang","year":"2018","unstructured":"Zhang L, et al. Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies. World J Surg Oncol. 2018;16(1):124.","journal-title":"World J Surg Oncol"},{"issue":"3","key":"1840_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1590\/S1677-5538.IBJU.2014.03.03","volume":"40","author":"RLR de La Roca","year":"2014","unstructured":"de La Roca RLR, et al. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome. Int Braz J Urol. 2014;40(3):306\u201315.","journal-title":"Int Braz J Urol"},{"issue":"1","key":"1840_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","volume":"77","author":"T Nyberg","year":"2020","unstructured":"Nyberg T, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol. 2020;77(1):24\u201335.","journal-title":"Eur Urol"},{"key":"1840_CR18","doi-asserted-by":"publisher","first-page":"p4986365","DOI":"10.1155\/2020\/4986365","volume":"2020","author":"C Messina","year":"2020","unstructured":"Messina C, et al. BRCA mutations in prostate cancer: prognostic and predictive implications. J Oncol. 2020;2020:p4986365.","journal-title":"J Oncol"},{"issue":"5","key":"1840_CR19","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215\u201328.","journal-title":"Cell"},{"issue":"4","key":"1840_CR20","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1172\/JCI132031","volume":"130","author":"J Mateo","year":"2020","unstructured":"Mateo J, et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest. 2020;130(4):1743\u201351.","journal-title":"J Clin Invest"},{"issue":"18","key":"1840_CR21","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1158\/1078-0432.CCR-20-0764","volume":"26","author":"H Kaur","year":"2020","unstructured":"Kaur H, et al. Genomic and clinicopathologic characterization of ATM-deficient prostate cancer. Clin Cancer Res. 2020;26(18):4869\u201381.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1840_CR22","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/ijc.33272","volume":"147","author":"D Woko\u0142orczyk","year":"2020","unstructured":"Woko\u0142orczyk D, et al. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in poland. Int J Cancer. 2020;147(10):2793\u2013800.","journal-title":"Int J Cancer"},{"issue":"5","key":"1840_CR23","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.eururo.2020.12.040","volume":"80","author":"MP Deek","year":"2021","unstructured":"Deek MP, et al. The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited. Eur Urol. 2021;80(5):632\u201340.","journal-title":"Eur Urol"},{"issue":"6","key":"1840_CR24","doi-asserted-by":"publisher","first-page":"e2671","DOI":"10.1016\/j.urolonc.2015.02.009","volume":"33","author":"SS Yadav","year":"2015","unstructured":"Yadav SS, et al. Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment. Urol Oncol. 2015;33(6):e2671\u201313.","journal-title":"Urol Oncol"},{"issue":"14","key":"1840_CR25","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1038\/onc.2014.115","volume":"34","author":"R Ferraldeschi","year":"2015","unstructured":"Ferraldeschi R, et al. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene. 2015;34(14):1745\u201357.","journal-title":"Oncogene"},{"issue":"6","key":"1840_CR26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/2159-8290.CD-17-0867","volume":"8","author":"HB Pearson","year":"2018","unstructured":"Pearson HB, et al. Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with pten loss to accelerate progression and castration-resistant growth. Cancer Discov. 2018;8(6):764\u201379.","journal-title":"Cancer Discov"},{"issue":"6","key":"1840_CR27","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2020.04.058","volume":"78","author":"C Herberts","year":"2020","unstructured":"Herberts C, et al. Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer. Eur Urol. 2020;78(6):834\u201344.","journal-title":"Eur Urol"},{"issue":"1","key":"1840_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamaneurol.2014.1973","volume":"72","author":"I Agalliu","year":"2015","unstructured":"Agalliu I, et al. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with parkinson disease: a pooled analysis. JAMA Neurol. 2015;72(1):58\u201365.","journal-title":"JAMA Neurol"},{"issue":"11","key":"1840_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1212\/WNL.0b013e318249f673","volume":"78","author":"R Inzelberg","year":"2012","unstructured":"Inzelberg R, et al. The LRRK2 G2019S mutation is associated with parkinson disease and concomitant non-skin cancers. Neurology. 2012;78(11):781\u20136.","journal-title":"Neurology"},{"issue":"10","key":"1840_CR30","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/jcb.24850","volume":"115","author":"W Lu","year":"2014","unstructured":"Lu W, Li Y. Salinomycin suppresses LRP6 expression and inhibits both Wnt\/\u03b2-catenin and mTORC1 signaling in breast and prostate cancer cells. J Cell Biochem. 2014;115(10):1799\u2013807.","journal-title":"J Cell Biochem"},{"issue":"5","key":"1840_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6004\/jnccn.2019.7307","volume":"17","author":"HH Cheng","year":"2019","unstructured":"Cheng HH, et al. Germline and somatic mutations in prostate cancer for the clinician. J Natl Compr Canc Netw. 2019;17(5):515\u201321.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10305","key":"1840_CR32","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, et al. Prostate cancer. Lancet. 2021;398(10305):1075\u201390.","journal-title":"Lancet"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01840-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:40:38Z","timestamp":1781613638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-025-01840-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1840"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01840-5","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Ethic Committee of the Seoul St. Mary`s Hospital (IRB number: KC24RISI0398). This study is a retrospective study based on medical records registered at St. Mary\u2019s Hospital in Seoul, and consent was not collected because it was not mandatory.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest regarding the current manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"166"}}